Femasys received FDA approval for an Investigational Device Exemption (IDE) to evaluate FemBloc in a pivotal clinical trial. This approval is a significant milestone for the company, as it allows them to proceed with the trial and potentially bring a new product to market. The news has a direct impact on Femasys' stock price, as it indicates progress in the company's product pipeline and increases the likelihood of future revenue generation.